Significant Agreements - Additional Information (Details) - USD ($)				1 Months Ended	3 Months Ended		12 Months Ended
	Jun. 16, 2021	Feb. 09, 2021	May 15, 2020	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Nov. 13, 2020	Dec. 15, 2016	Jul. 13, 2015	Jul. 16, 2014
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue, net of current portion					$ 100,000		$ 100,000
Deferred revenue, net of current portion ($100 and $100 from related party)					17,326,000		22,032,000
Accounts Receivable
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues					200,000		1,000,000.0
Contract assets
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues					400,000		200,000
Regulatory Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential milestone payment								$ 2,800,000
Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Future development, regulatory, and product launch milestones payment received			$ 200,000,000.0
Research and Development Expense
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Sublicensing expenses						$ 800,000
The Regents of the University of California/University of Vienna
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Clinical milestone payment					3,400,000
Reimbursement percentage										50.00%
Reduction in general and administrative expenses					1,100,000	1,600,000
The Regents of the University of California/University of Vienna | Research and Development Expense
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Sublicensing expenses					300,000
The Regents of the University of California/University of Vienna | General and Administrative Expense
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Patent prosecution and maintenance costs					2,300,000	3,200,000
Memorial Sloan Kettering Cancer Center
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment fee									$ 500,000
Commercial milestones									112,000,000.0
Aggregate success payment					35,000,000.0
Maximum value of success payments and control payment					35,000,000.0
Fair value of success payments liability					2,500,000
Increase decrease in fair value of success payments liability					$ 1,600,000	700,000
Memorial Sloan Kettering Cancer Center | Series B Convertible Preferred Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Share price					$ 5.1914
Memorial Sloan Kettering Cancer Center | Common Stock
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment fee									$ 2,100,000
Intellia Therapeutics, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment fee	$ 1,000,000.0
Percentage of other party's expenses												30.00%
Potential future milestone payments	$ 23,000,000.0
Intellia Therapeutics, Inc. | General and Administrative Expense | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Expenses incurred from transactions with related parties					$ 100,000	100,000
Intellia Therapeutics, Inc. | General and Administrative Expense | Patents
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Expenses incurred from transactions with related parties					300,000	$ 500,000
Pioneer Hi-Bred International, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront cash payment								500,000
Future contingent milestone payments											$ 22,400,000
Milestone Revenue				$ 300,000
Pioneer Hi-Bred International, Inc. | Sales Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential milestone payment								$ 20,000,000.0
Pioneer Hi-Bred International, Inc. | Research and Development Expense
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment for licensing revenue					0
Private Company License Agreement | Convertible Preferred Stock [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Convertible preferred stock issued			7,500,000
Fair value of equity			$ 7,500,000
Collaboration and License Agreement with AbbVie
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues					900,000
Future development, regulatory, and product launch milestones payment received		$ 15,000,000.0	$ 150,000,000.0
Upfront cash payment received					30,000,000.0		30,000,000.0
Deferred revenue, net of current portion					12,500,000		8,300,000
Deferred revenue, net of current portion ($100 and $100 from related party)					$ 14,500,000		$ 19,100,000